Delcath Systems DCTH
- Market cap
- $500.4M
- PE
- n/m
- a sliver of earnings
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $95.4M
- +36% on a year ago
- Net margin
- 0.6%
- Free cash flow yield
- 3.5%
Delcath Systems trades at 5.2× sales. Delcath Systems' PE is not meaningful: its earnings over the last year are a sliver against its price. Revenue was $95.4M over the last twelve months, up 36% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $434K−52% | $539K−16% | $3.1M+426% | $7.8M+1469% | $11.2M+2481% | $15.1M+2702% | $19.8M+530% | $24.2M+211% | $20.6M+84% | $20.7M+37% | $25M+26% | $29.1M+21% | |
| Cost of revenue | $133K−43% | $171K−28% | $903K+399% | $1.5M+913% | $1.6M+1133% | $2.1M+1143% | $2.8M+215% | $3.3M+118% | $2.6M+60% | $3M+42% | $3.7M+31% | $3M−10% |
| Gross profit | $301K−55% | $368K−9% | $2.2M+438% | $6.2M+1711% | $9.6M+3076% | $13M+3426% | $16.9M+658% | $20.8M+234% | $17.9M+88% | $17.7M+37% | $21.3M+26% | $26.1M+26% |
| R&D | $4.7M+15% | $4.7M+6% | $3.7M−19% | $3.4M−5% | $3.9M−17% | $2.9M−38% | $5M+35% | $6.9M+103% | $8M+107% | $9.4M+222% | $9.8M+96% | $10.4M+51% |
| SG&A | $6.2M+30% | $7M+82% | $8.8M+112% | $6.8M+41% | $7M+12% | $7M+1% | $11.3M+28% | $11.4M+68% | $10.3M+49% | $10.5M+50% | $13.1M+16% | $13.4M+18% |
| −$10.6M+29% | −$11.3M+44% | −$10.3M+24% | −$3.9M−51% | −$1.3M−88% | $3M | $642K | $2.6M | −$388K−69% | −$2.2M | −$1.6M | $2.4M−8% | |
| Interest expense | −$395K | −$15K | $199K−71% | $84K−77% | $113K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | −$11.1M | −$13.7M | $1.9M | −$3.4M | $1.3M | $3.2M | $375K−80% | −$1.3M−61% | −$908K | $3.2M−1% |
| n/a | n/a | $0 | $0 | $0 | $0 | $195K | $508K | −$455K | $562K | $162K−17% | $491K−3% | |
| Net income | −$20.3M+129% | −$11.1M+31% | −$11.1M+24% | −$13.7M+91% | $1.9M | −$3.4M−70% | $1.1M | $2.7M | $830K−56% | −$1.9M−44% | −$1.1M | $2.7M−1% |
| −$1.14+19% | −$0.49−43% | −$0.45−42% | −$0.48−17% | $0.06 | −$0.11−78% | $0.03 | $0.07 | $0.02−67% | −$0.05−55% | −$0.03 | $0.07+0% | |
| 17.9M+94% | 22.9M+133% | 24.9M+114% | 28.4M+128% | 32.3M+81% | 32M+40% | 39.5M+59% | 40.3M+42% | 40.1M+24% | 36.4M+14% | 36M−9% | 39.8M−1% |
EPS, diluted: 12 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Delcath Systems' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DCTHDelcath Systems | $500.4M | n/m | 200× | 5.2× | +36% | 0.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| Peer median | $552.7M | 22.3× | 24.1× | 2.0× | +4% | 7.8% |
More on Delcath Systems
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .